Q-omics provides the consensus-scored GCSHP2 profile across patient tissues and cancer cell-line models. GCSHP2 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, GCSHP2 is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, GCSHP2 RNA expression shows 6,417 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, LUSC, and STAD as cancer lineages where GCSHP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GCSHP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GCSHP2 survival associations across molecular data types. GCSHP2 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GCSHP2 RNA expression–survival associations across cancer types. High GCSHP2 expression shows unfavorable associations in ACC, CHOL, KIRC, COAD and KICH, but favorable associations in BLCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for GCSHP2 RNA expression.
This table summarizes GCSHP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for GCSHP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GCSHP2 shows higher tumor expression in LUSC. The LUSC box plot shows higher GCSHP2 RNA expression in tumor versus normal tissue (log2 FC = +0.015, t-test p = .030).
This table shows molecular features associated with GCSHP2 in patient tissues and cancer cell lines. In patient samples, GCSHP2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
